Cargando…

Differences in brain pathological changes between rotenone and 6-hydroxydopamine Parkinson’s disease models

Rotenone and 6-hydroxydopamine are two drugs commonly used to generate Parkinson’s disease animal models. They not only achieve degenerative changes of dopaminergic neurons in the substantia nigra, but also satisfy the requirements for iron deposition. However, few studies have compared the characte...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Lan-Xiang, Du, Dan, Wang, Zhan-Qiu, Fang, Yuan, Zheng, Tao, Dong, Yan-Chao, Shi, Qing-Lei, Zhao, Min, Xiao, Fang, Du, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065241/
https://www.ncbi.nlm.nih.gov/pubmed/30028338
http://dx.doi.org/10.4103/1673-5374.235076
_version_ 1783342825810690048
author Liu, Lan-Xiang
Du, Dan
Wang, Zhan-Qiu
Fang, Yuan
Zheng, Tao
Dong, Yan-Chao
Shi, Qing-Lei
Zhao, Min
Xiao, Fang
Du, Juan
author_facet Liu, Lan-Xiang
Du, Dan
Wang, Zhan-Qiu
Fang, Yuan
Zheng, Tao
Dong, Yan-Chao
Shi, Qing-Lei
Zhao, Min
Xiao, Fang
Du, Juan
author_sort Liu, Lan-Xiang
collection PubMed
description Rotenone and 6-hydroxydopamine are two drugs commonly used to generate Parkinson’s disease animal models. They not only achieve degenerative changes of dopaminergic neurons in the substantia nigra, but also satisfy the requirements for iron deposition. However, few studies have compared the characteristics of these two models by magnetic resonance imaging. In this study, rat models of Parkinson’s disease were generated by injection of 3 μg rotenone or 10 μg 6-hydroxydopamine into the right substantia nigra. At 1, 2, 4, and 6 weeks after injection, coronal whole-brain T2-weighted imaging, transverse whole-brain T2-weighted imaging, and coronal diffusion tensor weighted imaging were conducted to measure fractional anisotropy and T2(*) values at the injury site. The fractional anisotropy value on the right side of the substantia nigra was remarkably lower at 6 weeks than at other time points in the rotenone group. In the 6-hydroxydopamine group, the fractional anisotropy value was decreased, but T2(*) values were increased on the right side of the substantia nigra at 1 week. Our findings confirm that the 6-hydroxydopamine-induced model is suitable for studying dopaminergic neurons over short periods, while the rotenone-induced model may be appropriate for studying the pathological and physiological processes of Parkinson’s disease over long periods.
format Online
Article
Text
id pubmed-6065241
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-60652412018-08-09 Differences in brain pathological changes between rotenone and 6-hydroxydopamine Parkinson’s disease models Liu, Lan-Xiang Du, Dan Wang, Zhan-Qiu Fang, Yuan Zheng, Tao Dong, Yan-Chao Shi, Qing-Lei Zhao, Min Xiao, Fang Du, Juan Neural Regen Res Research Article Rotenone and 6-hydroxydopamine are two drugs commonly used to generate Parkinson’s disease animal models. They not only achieve degenerative changes of dopaminergic neurons in the substantia nigra, but also satisfy the requirements for iron deposition. However, few studies have compared the characteristics of these two models by magnetic resonance imaging. In this study, rat models of Parkinson’s disease were generated by injection of 3 μg rotenone or 10 μg 6-hydroxydopamine into the right substantia nigra. At 1, 2, 4, and 6 weeks after injection, coronal whole-brain T2-weighted imaging, transverse whole-brain T2-weighted imaging, and coronal diffusion tensor weighted imaging were conducted to measure fractional anisotropy and T2(*) values at the injury site. The fractional anisotropy value on the right side of the substantia nigra was remarkably lower at 6 weeks than at other time points in the rotenone group. In the 6-hydroxydopamine group, the fractional anisotropy value was decreased, but T2(*) values were increased on the right side of the substantia nigra at 1 week. Our findings confirm that the 6-hydroxydopamine-induced model is suitable for studying dopaminergic neurons over short periods, while the rotenone-induced model may be appropriate for studying the pathological and physiological processes of Parkinson’s disease over long periods. Medknow Publications & Media Pvt Ltd 2018-07 /pmc/articles/PMC6065241/ /pubmed/30028338 http://dx.doi.org/10.4103/1673-5374.235076 Text en Copyright: © Neural Regeneration Research http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Research Article
Liu, Lan-Xiang
Du, Dan
Wang, Zhan-Qiu
Fang, Yuan
Zheng, Tao
Dong, Yan-Chao
Shi, Qing-Lei
Zhao, Min
Xiao, Fang
Du, Juan
Differences in brain pathological changes between rotenone and 6-hydroxydopamine Parkinson’s disease models
title Differences in brain pathological changes between rotenone and 6-hydroxydopamine Parkinson’s disease models
title_full Differences in brain pathological changes between rotenone and 6-hydroxydopamine Parkinson’s disease models
title_fullStr Differences in brain pathological changes between rotenone and 6-hydroxydopamine Parkinson’s disease models
title_full_unstemmed Differences in brain pathological changes between rotenone and 6-hydroxydopamine Parkinson’s disease models
title_short Differences in brain pathological changes between rotenone and 6-hydroxydopamine Parkinson’s disease models
title_sort differences in brain pathological changes between rotenone and 6-hydroxydopamine parkinson’s disease models
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065241/
https://www.ncbi.nlm.nih.gov/pubmed/30028338
http://dx.doi.org/10.4103/1673-5374.235076
work_keys_str_mv AT liulanxiang differencesinbrainpathologicalchangesbetweenrotenoneand6hydroxydopamineparkinsonsdiseasemodels
AT dudan differencesinbrainpathologicalchangesbetweenrotenoneand6hydroxydopamineparkinsonsdiseasemodels
AT wangzhanqiu differencesinbrainpathologicalchangesbetweenrotenoneand6hydroxydopamineparkinsonsdiseasemodels
AT fangyuan differencesinbrainpathologicalchangesbetweenrotenoneand6hydroxydopamineparkinsonsdiseasemodels
AT zhengtao differencesinbrainpathologicalchangesbetweenrotenoneand6hydroxydopamineparkinsonsdiseasemodels
AT dongyanchao differencesinbrainpathologicalchangesbetweenrotenoneand6hydroxydopamineparkinsonsdiseasemodels
AT shiqinglei differencesinbrainpathologicalchangesbetweenrotenoneand6hydroxydopamineparkinsonsdiseasemodels
AT zhaomin differencesinbrainpathologicalchangesbetweenrotenoneand6hydroxydopamineparkinsonsdiseasemodels
AT xiaofang differencesinbrainpathologicalchangesbetweenrotenoneand6hydroxydopamineparkinsonsdiseasemodels
AT dujuan differencesinbrainpathologicalchangesbetweenrotenoneand6hydroxydopamineparkinsonsdiseasemodels